Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) has received mixed analyst ratings over the past three months, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target is $57.5, down from $60.50, with a high estimate of $61.00 and a low of $50.00. Analysts from Morgan Stanley, Benchmark, and HC Wainwright & Co. have adjusted their ratings and price targets. Halozyme is a biotech company focusing on oncology therapies. It has shown a revenue growth of 3.38%, a high net margin of 37.88%, an ROE of 40.9%, and an ROA of 4.42%, but carries a higher debt-to-equity ratio of 6.01 compared to the industry average.
December 26, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Halozyme Therapeutics has a mix of bullish and somewhat bullish ratings from analysts, with a lowered average price target of $57.5. The company's strong financial performance indicators may counterbalance the negative sentiment from the reduced price target.
While the average price target for HALO has decreased, indicating a bearish sentiment, the company's strong financial performance such as high net margin and ROE could provide a counteracting positive sentiment. The mixed analyst ratings and the recent positive financial results suggest a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100